Skip to main content
. 2019 Dec 24;12(Suppl 9):191. doi: 10.1186/s12920-019-0633-1

Table 8.

Survival analysis of three treatments on four BIC subtypes and three GBM subtypes

Treatment All Subtype1 Subtype2 Subtype3 Subtype4
Cytoxan(BIC) 3.3e-02 6.1e-01 4.5e-02 4.83e-01 5.01e-01
Adriamycin(BIC) 1.3e-02 2.77e-01 3.2e-02 8.21e-01 2.66e-01
Temozolomide(GBM) 3.6e-02 2.0e-02 9.18e-01 3.88e-01 ——

The treatment can significantly improve treatment outcomes in the subtype of p-value in boldface